Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHR | P34981 | 4/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27504186 | 0.97 | TRHR (0.41) | TRHRHDAC3HDAC11HDAC6HDAC1 | |
| SCHEMBL27448785 | 0.88 | TRHR (0.37) | TRHRHDAC3HDAC11HDAC6HDAC1 | |
| SCHEMBL7649422 | 0.85 | TRHR (0.43) | TRHRHDAC3HDAC11HDAC6HDAC1 | |
| SCHEMBL11816929 | 0.85 | TRHR (0.38) | TRHRHDAC3HDAC11HDAC6HDAC1 | |
| SCHEMBL11034489 | 0.83 | TRHR (0.44) | TRHR | |
| SCHEMBL29405912 | 0.81 | TRHR (0.46) | TRHR | |
| SCHEMBL6026783 | 0.81 | TRHR (0.46) | TRHR | |
| SCHEMBL27869228 | 0.81 | TRHR (0.46) | TRHR | |
| SCHEMBL6026780 | 0.81 | TRHR (0.46) | TRHR | |
| SCHEMBL11231582 | 0.81 | TRHR (0.41) | TRHRHDAC3HDAC11HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56059714-A | — | — | None | — | — | JP | disclosed |
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
| US-4299821-A | HYPOTHERMIC AGENTS, TREATMENT OF NARCOLEPSY | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1981-11-10 | — | — | US | disclosed |
| JP-S5659714-A | IMPROVER AND REMEDY FOR DYSBULIA OR DEPRESSION | TANABE SEIYAKU CO LTD | 1981-05-23 | — | — | JP | disclosed |
| US-3959248-A | TRIPEPTIDES; ANTIDEPRESSANTS | MERCK & CO., INC. (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | TRHR 1177/4885HDAC3 3530/4885HDAC11 3232/4885 |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | TRHR 1177/4885HDAC3 3530/4885HDAC11 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.